Fish oil in chronic psychiatric outpatients with anxiety and mood disorders.
Adjunctive natural low dose docosahexaenoic acid (DHA) omega-3 in a 16 week random double-blind placebo controlled (RDBPC) cross-over withdrawal study in a group of chronic, psychiatric out-patients with anxiety and mood disorders.
Dr Michael Piperoglou
60 participants
May 1, 2014
Interventional
Conditions
Summary
To investigate the effectiveness of the adjunctive role of DHA omega-3 in outpatients with chronic anxiety and depression.
Eligibility
Inclusion Criteria2
- Outpatients with chronic anxiety and/or depressive symptoms.
- Patients currently taking DHA (NeuroSpark) capsules for at least 3 months prior to study entry.
Exclusion Criteria8
- ADHD
- Brain injury
- Mild cognitive impairment
- Dementias
- Substance dependence and/or abuse
- Schizophrenia
- Acutely suicidal patients
- Chronic unstable medical conditions
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Natural low dose docosahexaenoic acid (DHA) omega-3 (NeuroSpark) 130-390mg per day in addition to standard psychiatric treatments. The dose in the study is the dose which has been found clinically to be appropriate and efficacious for each individual entering the study. Oral. This study medication will be administered for 16 weeks (24 week study minus 8 weeks on placebo = 16 weeks of study medication). There is no washout period. Adherence to study medication regimen will be monitored via capsule return and self-report daily diary entries.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000390684